全文获取类型
收费全文 | 4547篇 |
免费 | 245篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 61篇 |
儿科学 | 335篇 |
妇产科学 | 43篇 |
基础医学 | 359篇 |
口腔科学 | 151篇 |
临床医学 | 326篇 |
内科学 | 889篇 |
皮肤病学 | 47篇 |
神经病学 | 246篇 |
特种医学 | 121篇 |
外国民族医学 | 1篇 |
外科学 | 985篇 |
综合类 | 148篇 |
一般理论 | 2篇 |
预防医学 | 249篇 |
眼科学 | 145篇 |
药学 | 374篇 |
中国医学 | 23篇 |
肿瘤学 | 307篇 |
出版年
2023年 | 49篇 |
2022年 | 48篇 |
2021年 | 217篇 |
2020年 | 119篇 |
2019年 | 168篇 |
2018年 | 206篇 |
2017年 | 134篇 |
2016年 | 166篇 |
2015年 | 173篇 |
2014年 | 234篇 |
2013年 | 297篇 |
2012年 | 434篇 |
2011年 | 435篇 |
2010年 | 234篇 |
2009年 | 194篇 |
2008年 | 276篇 |
2007年 | 255篇 |
2006年 | 214篇 |
2005年 | 162篇 |
2004年 | 155篇 |
2003年 | 127篇 |
2002年 | 100篇 |
2001年 | 49篇 |
2000年 | 35篇 |
1999年 | 22篇 |
1998年 | 16篇 |
1997年 | 6篇 |
1996年 | 7篇 |
1995年 | 10篇 |
1994年 | 5篇 |
1993年 | 8篇 |
1992年 | 20篇 |
1991年 | 18篇 |
1990年 | 13篇 |
1989年 | 24篇 |
1988年 | 11篇 |
1987年 | 9篇 |
1986年 | 10篇 |
1985年 | 10篇 |
1984年 | 5篇 |
1982年 | 6篇 |
1981年 | 6篇 |
1979年 | 7篇 |
1976年 | 6篇 |
1974年 | 9篇 |
1972年 | 9篇 |
1971年 | 10篇 |
1969年 | 14篇 |
1928年 | 4篇 |
1927年 | 4篇 |
排序方式: 共有4812条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
Lu Victor M. O’Connor Kyle P. Shah Ashish H. Eichberg Daniel G. Luther Evan M. Komotar Ricardo J. Ivan Michael E. 《Journal of neuro-oncology》2020,148(2):221-229
Journal of Neuro-Oncology - The most recent cIMPACT-NOW update highlighted the homozygous deletion of the Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) gene as a clinically important molecular... 相似文献
5.
6.
Kuldip D. Upadhyay Narsinh M. Dodia Rupesh C. Khunt Ravi S. Chaniara Anamik K. Shah 《Chemical biology & drug design》2019,94(3):1647-1655
A series of pyrano[3,2 c]quinoline was evaluated for its in vivo efficacy as TNF‐α inhibitor using LPS, phosphodiesterase (PDE)‐4, and CIA assays in different mice/rat models. The synthesis was performed using one‐pot multicomponent condensation between 2,4‐dihydroxy‐1‐methylquinoline, malononitrile, and diverse un(substituted) aromatic aldehydes. In vivo efficacy of the title compounds was evaluated using LPS assay in BALB/c mice, PDE4 inhibition in ketamine–xylazine‐induced anesthetize SD rats, and CIA assay was performed in DBA/1J mice as per the standard literature protocols. The outcome of the study revealed that compound 4v was found to be most promising candidate of the series. It was efficacious with 48.8 ± 13.0% inhibition of TNF‐α release at 100 mg/kg p.o., in the LPS assay in Balb/c mice model. It was effective in PDE4 assay in ketamine–xylazine‐induced anesthetize SD rats with duration of 38.3 ± 4.5 min for reversal of anesthetic effect and also showed significant inhibition of PDE4 in salbutamol treated U937 cell assay. It was also abolished TNF‐α induced phosphorylation and degradation of IκBα. Ultimately, its effect on CIA‐related bone and cartilage damage was found statistically similar to Enbrel. 相似文献
7.
8.
9.
Rimesh Pal Naresh Sachdeva Soham Mukherjee Vikas Suri Deepy Zohmangaihi Sant Ram Goverdhan Dutt Puri Ashish Bhalla Shiv Lal Soni Navin Pandey Anil Bhansali Sanjay Kumar Bhadada 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(1):193-196
Background and aimsPatients with diabetes mellitus (DM) often demonstrate impaired antibody response to influenza/hepatitis B vaccines. Hence, we compared anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with and without type 2 diabetes mellitus (T2DM).MethodsRecords of non-severe COVID-19 patients admitted at our institution between April 10, 2020 and May 20, 2020 were retrieved. Qualitative detection of total (IgG + IgM) anti-SARS-CoV-2 antibody was performed using electrochemiluminescence immunoassay in plasma samples collected at least 14 days post-polymerase chain reaction (PCR) confirmation of diagnosis.ResultsThirty-one non-severe COVID-19 patients were included. Nine patients (29%) had T2DM with mean HbA1c at admission of 8.3 ± 1.0%. Anti-SARS-CoV-2 antibody was estimated at a median of 16 (14–17) days post-PCR confirmation of COVID-19 diagnosis. Only three patients (10%) were seronegative, and all had T2DM. Patients with T2DM were more likely to have non-detectable anti-SARS-CoV-2 antibodies than those without DM (p = 0.019).ConclusionsCOVID-19 patients with T2DM may not undergo seroconversion even after two weeks of diagnosis. Impaired seroconversion could theoretically increase the risk of reinfections in patients with DM. However, the finding requires validation in large-scale studies involving serial estimations of anti-SARS-CoV-2 antibodies in patients with and without DM. 相似文献
10.